Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
AMES, Iowa, April 13, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK), today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on its clinical and development activities.
NewLink Genetics' senior management team will host the conference call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks.
Access to the live conference call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at http://edge.media-server.com/m/p/qa52gxjk. A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 7503837.
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics’ product candidates are designed to harness multiple components of the immune system to combat cancer. For more information, please visit http://www.newlinkgenetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include any statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2016 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink' Genetics' views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.
Investor Contacts: Lisa Miller Director of Investor Relations NewLink Genetics (515) 598-2555 [email protected] Beth Kurth LaVoieHealthScience 617-374-8800, ext. 106 [email protected] Allison Chen LaVoieHealthScience 617-374-8800, ext. 104 [email protected]
